Загрузка...
Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
BACKGROUND: Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma with one or more prior lines of therapy. CASE PRESE...
Сохранить в:
| Опубликовано в: : | Exp Hematol Oncol |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5804097/ https://ncbi.nlm.nih.gov/pubmed/29445583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0096-7 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|